An FDA advisory panel on Monday voted in favor of donanemab as a treatment for early symptomatic Alzheimer’s disease.In a press conference on June 10, the Peripheral and Central Nervous System Drugs Advisory Committee ruled 11-0 that donanemab (Eli Lilly & Co.), a once-per-month, 30-minute infusion treatment, was effective in treating individuals with mild cognitive impairment and mild
Independent committee recommends the FDA approve Eli Lilly's Alzheimer's drug donanemab cnn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from cnn.com Daily Mail and Mail on Sunday newspapers.
FDA advisers endorse Eli Lilly's early-stage Alzheimer's drug donanemab ktvz.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from ktvz.com Daily Mail and Mail on Sunday newspapers.